Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
Details for Australian Patent Application No. 2003248558 (hide)
International Classifications
Event Publications
16 October 2003 Complete Application Filed
Priority application(s): 60/382,781 21.05.02 US; 60/459,332 31.03.03 US
5 February 2004 Application Open to Public Inspection
Published as AU-B-2003248558
12 March 2009 Application Accepted
Published as AU-B-2003248558
9 July 2009 Standard Patent Sealed
9 July 2009 Corrigenda
Applications Accepted - Name Index Under the name CV Therapeutics, Inc., Application No. 2003248558, under INID (54) correct the title to read Method of treating diabetes Corrigenda
15 October 2009 Amendment Made
The nature of the amendment is: Amend the patentee name from CV Therapeutics, Inc. to Gilead Palo Alto, Inc.
2 February 2012 Assignment Registered
Gilead Palo Alto, Inc. The patent has been assigned to Gilead Sciences Inc.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2003248559-DEVICE FOR WAVELENGTH-SELECTIVE IMAGING
2003248557-SHAPE BASED NOISE CHARACTERIZATION AND ANALYSIS OF LSI
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser